Long-term safety profile and secondary effectiveness of canakinumab in pediatric rheumatic diseases: a single-center experience.
Elif Kılıc KonteNergis AkayUmit GulKubra UcakEcenur Izzete DereliogluDamla GürleyikEsma AslanAybüke GunalpFatih HaslakMehmet YildizAmra AdrovicSezgin ŞahinKenan BarutOzgur KasapcopurPublished in: Expert opinion on drug safety (2024)
An increase in side effect was not observed with the increasing cumulative doses of canakinumab. Canakinumab demonstrated long-term safety with appropriate indication and monitoring.